Search
Zanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigational[A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903] … [A264718] It has been investigated for the treatment of HER2-positive solid tumors, including gastroesophageal, colorectal, and biliary tract cancers.
Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODYCategories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsDeferoxamine
go.drugbank.com/drugs/DB00746ApprovedInvestigationalNatural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Products: Desferal 500mg Powder for Solution for Injection, Deferoxamine Mesylate for InjectionTeclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Products: Tecvayli 90 mg/mL Solution for Injection, Tecvayli 10 mg/mL Solution for InjectionPertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).
Mixtures: PHESGO Solution for Subcutaneous Injection 600mg/600mg/10mL, PHESGO Solution for Subcutaneous Injection 1200mg/600mg/15mLCategories: HER2 Receptor Antagonists, Receptor, ErbB-2, antagonists & inhibitorsTigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalTigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was gra...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion, TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIALTozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigationalIt is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19. … [L26956] Fact sheets for caregivers, recipients, and healthcare providers are now available.
Mixtures: Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose Concentrate for Dispersion for Injection, Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose Dispersion for InjectionProducts: Comirnaty 3mcg Concentrate for Dispersion for Injection, Comirnaty LP.8.1 30 micrograms/dose Dispersion for InjectionPasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Categories: Somatostatin Receptor AgonistsProducts: SIGNIFOR LAR(60 MG POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION), SIGNIFOR LAR POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 40MGEribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic … Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Products: Halaven Solution for Injection 0.5mg/mL, HALAVEN 0.5 mg/ml solution for injectionDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalModifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Dalbavancin Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Dalbavancin ratiopharm 500 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungSodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedInvestigationalSodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of ...
Mixtures: KABIVEN EMULSION FOR INFUSION, SmofKabiven Emulsion for InfusionProducts: GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216 mg/ml, Glycophos Concentrate for Solution for Infusion 216mg/ml